Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-04-01, Stock:JNJ, The news for the past five days is as follows:
2019-03-25: NEWS1: Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know.NEWS2: Oklahoma top court clears way for Purdue, J&J, Teva to face opioid trial.NEWS3: Johnson & Johnson (JNJ): Are Hedge Funds Right About This Stock?.NEWS4: Markets Right Now: Stock indexes end an indecisive day mixed.NEWS5: Raymond James Expects Johnson & Johnson's Growth To Accelerate Into 2020.NEWS6: Johnson & Johnson and Bayer settle Xarelto lawsuits for $775 million.NEWS7: European shares slip for fourth day on growth, Brexit concerns.NEWS8: US experts revisit breast implant safety after new concerns.NEWS9: J&J Files Application for Darzalex Label Expansion in Europe.NEWS10: J&J Files Application for Darzalex Label Expansion in Europe.NEWS11: Settlement Reached Resolving Xarelto Multidistrict Litigation Claims.NEWS12: Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 million.NEWS13: Markets Right Now: US stock indexes turn mixed.NEWS14: Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 million.NEWS15: Bayer, J&J settle U.S. Xarelto litigation for $775 million.NEWS16: Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 mln.NEWS17: J&J Files Application for Darzalex Label Expansion in Europe.NEWS18: S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion.NEWS19: Health Care Sector Update for 03/25/2019: NK, MDWD, AIMT, JNJ, PFE, ABT, MRK, AMGN.NEWS20: Health Care Sector Update for 03/25/2019: NK, MDWD, AIMT, JNJ, PFE, ABT, MRK, AMGN.NEWS21: Markets Right Now: US stocks open slightly higher.NEWS22: Alcon Inc. -- Moody's assigns Baa2 issuer rating to Alcon; stable outlook.
2019-03-26: NEWS1: Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million.NEWS2: Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million.NEWS3: Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote.NEWS4: Purdue Pharma agrees to $270 million settlement in Oklahoma opioid case.NEWS5: Purdue Pharma agrees to $270 mln settlement in Oklahoma opioid case.NEWS6: Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million.NEWS7: 5 Must-See Stock Charts: Oil, JNJ, BBBY, CCL, and NIO.NEWS8: Dow Jones Climbs As One Of Its Maligned Stocks Nears Buy Point.NEWS9: OxyContin Maker Purdue Pharma Agrees to $270 Million Settlement With Oklahoma.NEWS10: Health Care Sector Update for 03/26/2019: ALDX, ZOM, CANF, NNVC, JNJ, PFE, ABT, MRK, AMGN.NEWS11: Health Care Sector Update for 03/26/2019: ALDX, ZOM, CANF, NNVC, JNJ, PFE, ABT, MRK, AMGN.NEWS12: OxyContin maker Purdue agrees to settle Oklahoma opioid case - source.NEWS13: Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know.NEWS14: Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know.
2019-03-27: NEWS1: New Jersey jury finds J&J not liable in latest talc cancer trial.NEWS2: J&J settles three mesothelioma talc cases-plaintiffs' lawyer.NEWS3: New Jersey jury finds J&J not liable in latest talc cancer trial.NEWS4: 5 Cancer-Fighting Stocks to Boost Portfolio Gains.NEWS5: 5 Cancer-Fighting Stocks to Boost Portfolio Gains.NEWS6: Johnson & Johnson Vision Announces Availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY in the U.S..NEWS7: 5 Cancer-Fighting Stocks to Boost Portfolio Gains.NEWS8: 6 Gene Therapy M&A Targets On The Radar.NEWS9: J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group.NEWS10: J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group.NEWS11: iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow.NEWS12: iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow.NEWS13: 3 Reasons Why Johnson & Johnson (JNJ) Is a Great Growth Stock.NEWS14: 3 Reasons Why Johnson & Johnson (JNJ) Is a Great Growth Stock.NEWS15: Axsome Adds To Strong Gains After FDA Grants Breakthrough Designation For Depression Drug.NEWS16: J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group.NEWS17: Health Care Sector Update for 03/27/2019: AXSM, BLRX, WCG, CNC, JNJ, PFE, ABT, MRK, AMGN.NEWS18: Health Care Sector Update for 03/27/2019: AXSM, BLRX, WCG, CNC, JNJ, PFE, ABT, MRK, AMGN.NEWS19: 3 Reasons Why Johnson & Johnson (JNJ) Is a Great Growth Stock.NEWS20: 5 Must-See Stock Charts: Oil, JNJ, BBBY, CCL, and NIO.NEWS21: 5 Must-See Stock Charts: Oil, JNJ, BBBY, CCL, and NIO.
2019-03-28: NEWS1: New York sues billionaire family behind maker of OxyContin.NEWS2: New York sues billionaire family behind maker of OxyContin.NEWS3: AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes.NEWS4: AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes.NEWS5: More Mud on Johnson & Johnson?.NEWS6: The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals.NEWS7: The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals.NEWS8: Johnson & Johnson Vision Announces Availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY in Canada.NEWS9: State's opioid suit hits billionaire family behind OxyContin.NEWS10: This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock.NEWS11: This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock.NEWS12: AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes.NEWS13: NY opioid lawsuit hits billionaire family behind OxyContin.NEWS14: The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals.NEWS15: 3 Small Biotech Stocks Hitting New Highs.NEWS16: Health Care Sector Update for 03/28/2019: CTST, AMRN, VLRX, JNJ, PFE, ABT, MRK, AMGN.NEWS17: Health Care Sector Update for 03/28/2019: CTST, AMRN, VLRX, JNJ, PFE, ABT, MRK, AMGN.NEWS18: Johnson & Johnson prevails in New Jersey talc cancer trial.NEWS19: This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock.NEWS20: PRESS DIGEST- New York Times business news - March 28.NEWS21: J&J&apos;s Sudden Talc-Cancer Settlements Aren&apos;t Its Usual Style.NEWS22: New York sues Purdue Pharma and Sackler family over opioid crisis.NEWS23: New Jersey jury finds J&J not liable in talc cancer trial; company settles 3 other cases.NEWS24: New Jersey jury finds J&J not liable in talc cancer trial; company settles three other cases.
2019-03-29: NEWS1: AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo.NEWS2: AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo.NEWS3: AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo.NEWS4: Dow 30 Stock Roundup: Apple Launches New Services, JPMorgan to Trim Wealth Jobs.NEWS5: Dow 30 Stock Roundup: Apple Launches New Services, JPMorgan to Trim Wealth Jobs.NEWS6: Health Care Sector Update for 03/29/2019: SEEL, VTVT, AZN, JNJ, PFE, ABT, MRK, AMGN.NEWS7: Health Care Sector Update for 03/29/2019: SEEL, VTVT, AZN, JNJ, PFE, ABT, MRK, AMGN.NEWS8: Axsome's Depression Drug Gets Breakthrough Therapy Status.NEWS9: Axsome's Depression Drug Gets Breakthrough Therapy Status.

Answer: Decrease